Johnson & Johnson, a pharmaceutical, and medical technologies corporation, completed the acquisition of acquire Shockwave Medical, a provider of innovative intravascular lithotripsy technology for the treatment of calcified CAD and PAD, for $13.1bn. “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world,” Joaquin Duato, Johnson & Johnson Chairman and CEO.